Lucid Diagnostics Analyst Ratings
Lucid Diagnostics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 177.78% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 177.78% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 94.44% | Needham | → $2.8 | Reiterates | Buy → Buy |
| 05/17/2023 | 177.78% | Cantor Fitzgerald | $4.5 → $4 | Maintains | Overweight |
| 05/17/2023 | 94.44% | Needham | $2.6 → $2.8 | Maintains | Buy |
| 04/21/2023 | 80.56% | Needham | → $2.6 | Reiterates | → Buy |
| 03/14/2023 | 80.56% | Needham | $3.1 → $2.6 | Maintains | Buy |
| 11/18/2022 | 143.06% | BTIG | $5 → $3.5 | Maintains | Buy |
| 11/15/2022 | 115.28% | Needham | $4.25 → $3.1 | Maintains | Buy |
| 08/16/2022 | 195.14% | Needham | $5 → $4.25 | Maintains | Buy |
| 05/12/2022 | 247.22% | Needham | $7 → $5 | Maintains | Buy |
| 03/29/2022 | 733.33% | Canaccord Genuity | $18 → $12 | Maintains | Buy |
| 03/29/2022 | 386.11% | Needham | $13 → $7 | Maintains | Buy |
| 12/27/2021 | 1011.11% | Ascendiant Capital | → $16 | Initiates Coverage On | → Buy |
| 12/15/2021 | 802.78% | Needham | $17 → $13 | Maintains | Buy |
| 11/08/2021 | 872.22% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1150% | Canaccord Genuity | → $18 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1358.33% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 1080.56% | Needham | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月22日 | 177.78% | 康托·菲茨杰拉德 | →$4 | 重申 | 超重→超重 |
| 08/16/2023 | 177.78% | 康托·菲茨杰拉德 | →$4 | 重申 | 超重→超重 |
| 08/16/2023 | 94.44% | 李约瑟 | →$2.8 | 重申 | 购买→购买 |
| 2023年05月17日 | 177.78% | 康托·菲茨杰拉德 | $4.5→$4 | 维护 | 超重 |
| 2023年05月17日 | 94.44% | 李约瑟 | $2.6→$2.8 | 维护 | 买 |
| 04/21/2023 | 80.56% | 李约瑟 | →$2.6. | 重申 | →购买 |
| 03/14/2023 | 80.56% | 李约瑟 | $3.1→$2.6 | 维护 | 买 |
| 2022年11月18日 | 143.06% | BTIG | $5→$3.5 | 维护 | 买 |
| 2022年11月15日 | 115.28% | 李约瑟 | $4.25→$3.1 | 维护 | 买 |
| 08/16/2022 | 195.14% | 李约瑟 | $5→$4.25 | 维护 | 买 |
| 2022年05月12日 | 247.22% | 李约瑟 | $7→$5 | 维护 | 买 |
| 03/29/2022 | 733.33% | 卡纳科特·格纳奇 | $18→$12 | 维护 | 买 |
| 03/29/2022 | 386.11% | 李约瑟 | $13→$7 | 维护 | 买 |
| 2021年12月27日 | 1011.11% | 《上升之都》 | →$16 | 开始承保 | →购买 |
| 2021年12月15日 | 802.78% | 李约瑟 | $17→$13 | 维护 | 买 |
| 11/08/2021 | 872.22% | BTIG | →$14 | 开始承保 | →购买 |
| 11/08/2021 | 1150% | 卡纳科特·格纳奇 | →$18 | 开始承保 | →购买 |
| 11/08/2021 | 1358.33% | 康托·菲茨杰拉德 | →$21 | 开始承保 | →超重 |
| 11/08/2021 | 1080.56% | 李约瑟 | →$17 | 开始承保 | →购买 |
What is the target price for Lucid Diagnostics (LUCD)?
Lucid Diagnostics(LUCD)的目标价是多少？
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $4.00 expecting LUCD to rise to within 12 months (a possible 177.78% upside). 9 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年8月22日报道了Lucid Diagnostics(纳斯达克：LUCD)的最新目标价。这家分析公司将目标价定为4美元，预计LUCD将在12个月内升至(可能上涨177.78%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
Lucid诊断公司(LUCD)的最新分析师评级是多少？
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Cantor Fitzgerald, and Lucid Diagnostics reiterated their overweight rating.
纳斯达克(Sequoia Capital：LUCD)的最新分析师评级由康托·菲茨杰拉德提供，Lucid Diagnostics重申其增持评级。
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Lucid Diagnostics(LUCD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Lucid Diagnostics的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Lucid Diagnostics的上一次评级是在2023年8月22日提交的，因此您应该预计下一次评级将在2024年8月22日左右提供。
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
分析师评级清醒诊断(LUCD)正确吗？
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a reiterated with a price target of $0.00 to $4.00. The current price Lucid Diagnostics (LUCD) is trading at is $1.44, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的清醒诊断(LUCD)评级被重申，目标价在0.00美元至4.00美元之间。目前Lucid Diagnostics(LUCD)的交易价格为1.44美元，在分析师的预测范围内。